摘要
目的:观察骨痹通方治疗膝骨关节炎的疗效和安全性。方法:将120例膝骨关节炎患者随机分为骨痹通治疗组和盐酸氨基葡萄糖对照组,分别于治疗前及疗程结束后测定和记录患者疼痛、关节僵硬、关节功能障碍的平均骨关节炎指数、临床症状改善情况及患者和医生对病情的总体评价,检测ESR、CRP水平,进行血尿常规、肝肾功能检查,记录服药期间的不良反应。结果:治疗前后测患者的平均骨关节炎指数、VAS患者和医生对病情的总体评价差异有统计学意义(P<0.05),治疗组较对照组改善WOMAC指数更为明显;两组ESR、CRP水平及不良反应未显示差异,血、尿常规、肝肾功能检查治疗前后均未见异常。结论:骨痹通方具有缓解和改善疼痛、僵硬、关节功能障碍的作用,是治疗膝骨关节炎安全且行之有效的方剂。
Objective：To observe the therapeutic effect and safety of gubitong recipe（GBT） in treating osteoarthritis （OA） of knee joint. Methods ：120 patients with knee osteoarthritis were equally assigned, according to randomizing digital table, to the treatment group and the control group. The treatment group was treated with GBT Decoction and the control group with glucosamine hydroehloride. WOMAC （ Western Ontario and McMaster Universities Osteoarthritis Index, an index reflecting the degree of joint pain, stiffness, and dysfunction） in patients was assessed before and after treatment, besides, the improvement of patients＇symptoms and the integral estimation by doctors and patients were evaluated by visual analogue scale （VAS） as well. Moreover, erythrocyte sedimentation rate （ESR） , C-reactive protein （CRP） , blood and urinary routine tests, liver and kidney function examination, and the adverse reaction that occurred in the treatment period were observed. Results：WOMAC index and integral VAS value were lowered in both groups after treatment, showing significant statistical difference （ P 〈 0.05 ） compared with those before treatment, but the decrease of WOMAC index in the treatment group was more significant than that in the control group; ESR and CRP levels remained unchanged in all patients. No evident adverse reaction occurred in the treatment period. The safety indexes were all normal, including blood and urinary routine tests, liver and kidney function examination. Conelusion：GBT is a safe and effective recipe for the treatment of osteoarthritis of knee joint, which could alleviate the joint pain, stiffness, and dysfunction.
出处
《风湿病与关节炎》
2012年第4期11-14,共4页
Rheumatism and Arthritis
基金
北京市中医药科技发展基金
